

Message

---

**From:** Beck, Nancy [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=168ECB5184AC44DE95A913297F353745-BECK, NANCY]  
**Sent:** 3/22/2019 12:56:48 PM  
**To:** Tyree, JamesN [tyree.jamesn@epa.gov]; Bertrand, Charlotte [Bertrand.Charlotte@epa.gov]; Baptist, Erik [baptist.erik@epa.gov]  
**CC:** Hanley, Mary [Hanley.Mary@epa.gov]  
**Subject:** RE: By 11 am tomorrow: Review draft HHS (Breyse and Birnbaum) testimonies for SEPW PFAS hearing next week  
**Attachments:** MJ-116-15 NIH testimony for EPW PFAS hearing.2.docx

I looked only at the highlights and have edits on the NIH testimony.

Charlotte may be looking as well but lets get it to them in pieces so we don't miss the 11am deadline.

Thanks.

Nancy

---

Nancy B. Beck, Ph.D., DABT  
Principal Deputy Assistant Administrator, OCSP  
P: 202-564-1273  
[beck.nancy@epa.gov](mailto:beck.nancy@epa.gov)

---

**From:** Tyree, JamesN  
**Sent:** Friday, March 22, 2019 8:11 AM  
**To:** Beck, Nancy <Beck.Nancy@epa.gov>; Bertrand, Charlotte <Bertrand.Charlotte@epa.gov>; Baptist, Erik <Baptist.Erik@epa.gov>  
**Cc:** Hanley, Mary <Hanley.Mary@epa.gov>  
**Subject:** FW: By 11 am tomorrow: Review draft HHS (Breyse and Birnbaum) testimonies for SEPW PFAS hearing next week

Hi,

**For review this morning**, please see attached for draft testimony for Pat Breyse (ATSDR) and Linda Birnbaum (NIEHS) for next week's Senate EPW PFAS hearing at which Dave Ross is also testifying. (DOD's testimony came around earlier this week and was identical to previously cleared text.)

Both testimonies consist largely of prior cleared text (CDC from a November 13, 2018, field hearing before Senator Gary Peters, Ranking Member of the Federal Spending Oversight Subcommittee of the Committee on Homeland Security and Governmental Affairs; NIH from a September 26, 2018, hearing before the Senate Homeland Security and Governmental Affairs Subcommittee on Federal Spending Oversight and Emergency Management). In each draft, the highlighted text is NEW and regular text was previously cleared.

James

---

**From:** Klasen, Matthew  
**Sent:** Thursday, March 21, 2019 10:31 AM  
**To:** Emmerson, Caroline <Emmerson.Caroline@epa.gov>; Ingram, Amir <Ingram.Amir@epa.gov>; Folkemer, Nathaniel <Folkemer.Nathaniel@epa.gov>; Linkins, Samantha <Linkins.Samantha@epa.gov>; Harwood, Jackie <Harwood.Jackie@epa.gov>; Keller, Melanie <Keller.Melanie@epa.gov>; Hanley, Mary <Hanley.Mary@epa.gov>; Keller, Kaitlin <keller.kaitlin@epa.gov>; Wehling, Carrie <Wehling.Carrie@epa.gov>; Brazauskas, Joseph <brazauskas.joseph@epa.gov>; Block, Molly <block.molly@epa.gov>; Drinkard, Andrea <Drinkard.Andrea@epa.gov>; Grantham, Nancy <Grantham.Nancy@epa.gov>; Holsinger, Hannah <Holsinger.Hannah@epa.gov>

**Cc:** Levine, Carolyn <Levine.Carolyn@epa.gov>; Moody, Christina <Moody.Christina@epa.gov>; Richardson, RobinH <Richardson.RobinH@epa.gov>; Lyons, Troy <lyons.troy@epa.gov>; Frye, Tony (Robert) <frye.robert@epa.gov>; Voyles, Travis <Voyles.Travis@epa.gov>; Knapp, Kristien <Knapp.Kristien@epa.gov>; Spraul, Greg <Spraul.Greg@epa.gov>; Kramer, Jessica L. <kramer.jessical@epa.gov>; Wadlington, Christina <Wadlington.Christina@epa.gov>; McClain, Jennifer <McClain.Jennifer@epa.gov>; Frye, Tony (Robert) <frye.robert@epa.gov>; Borum, Denis <Borum.Denis@epa.gov>; Kaiser, Sven-Erik <Kaiser.Sven-Erik@epa.gov>; Skane, Elizabeth <Skane.Elizabeth@epa.gov>; Janifer, Pamela <Janifer.Pamela@epa.gov>; Snyder, Raquel <Snyder.Raquel@epa.gov>; Corr, Elizabeth <Corr.Elizabeth@epa.gov>

**Subject:** By 11 am tomorrow: Review draft HHS (Breyse and Birnbaum) testimonies for SEPW PFAS hearing next week

**Importance:** High

Hi folks,

**For review**, please see attached for draft testimony for Pat Breyse (ATSDR) and Linda Birnbaum (NIEHS) for next week's Senate EPW PFAS hearing at which Dave Ross is also testifying. (DOD's testimony came around earlier this week and was identical to previously cleared text.)

See below for some explanatory information from OMB, which mentions that the attached docs include highlighting to distinguish text that is identical to prior testimony language vs. language that is different. We should comment on previously cleared text only where we have significant issues.

**Please let me know if you have any comments by 11 am tomorrow (Friday), as OMB's deadline is soon after that.** Let me know if you have any questions.

Thanks,  
Matt

-----  
Matt Klasen  
U.S. Environmental Protection Agency  
Office of Congressional Affairs  
WJC North 3443P  
202-566-0780  
cell (202) 505-0787

---

### ***Clarifying Instructions from OMB***

Attached for your review, please find two draft HHS testimonies from NIH and CDC for a March 28th hearing before the Senate Committee on Environment and Public Works regarding the Federal response to the risks associated with per- and polyfluoroalkyl substances (PFAS). The NIH testimony (Birnbaum) is a 27-page draft and the CDC testimony (Breyse) is a 7-page draft.

Both testimonies consist largely of prior cleared text (CDC from a November 13, 2018, field hearing before Senator Gary Peters, Ranking Member of the Federal Spending Oversight Subcommittee of the Committee on Homeland Security and Governmental Affairs; NIH from a September 26, 2018, hearing before the Senate Homeland Security and Governmental Affairs Subcommittee on Federal Spending Oversight and Emergency Management). **In each draft, the highlighted text is NEW and regular text was previously cleared.**

The NIH testimony discusses the National Institute of Environmental Health Sciences (NIEHS) and its responsibilities under the Superfund Amendments and Reauthorization Act of 1986 (SARA) and the Superfund Research Program (SRP); its scientific research investigating health effects associated with human exposures to PFAS; the PFAS class of chemicals; the health effects associated with PFAS exposures; the NIEHS Extramural PFAS Research Portfolio; time-sensitive research opportunities related to PFAS; the NTP Responsive Evaluation and Assessment of Chemical Toxicity, or REACT, Program; research challenges; and Federal collaboration. The CDC testimony discusses the role of the Agency for Toxic Substances and Disease Registry (ATSDR) in investigating exposure to and possible health effects associated with PFAS contamination and current activities relating to PFAS exposure that were authorized through the National Defense Authorization Acts and Consolidated Appropriations Acts.